172
KNDP 당뇨병 임상 진료지침 Clinical Practice Guidelines

21. Davis TM, Brown SG, Jacobs IG, et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab 2010;95:2240-7.
22. Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract 2010;87:64-8.
23. Slama G, Traynard PY, Desplanque N, et al. The search for an optimized treatment of hypoglyce-mia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med 1990;150:589-93.
24. Wiethop BV, Cryer PE. Alanine and terbutaline in treatment of hypoglycemia in IDDM. Diabetes Care 1993;16:1131-6.
25. BrodowS RG, Williams C, Amatruda JM. Treatment of insulin reactions in diabetics. JAMA 1984;252: 3378-81.
26. Special problems. In: Skyler JS, editor. Medical Management of Type 1 Diabetes, 3rd ed. Alexan-dria, VA: American Diabetes Association; 1998, p. 134-43.
27. Canadian Diabetes Association. The role of dietary sugars in diabetes mellitus. Beta Release 1991;15: 117-23.
28. Gunning RR, Garber AJ. Bioactivity of instant glu-cose. Failure of absorption through oral mucosa. JAMA 1978;240:1611-2.
29. Glucobay® (acarbose) [product monograph]. To-ronto, ON: Bayer Inc.;2007.
30. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994;17:734-55.
31. Glucagon [product monograph]. Toronto, ON: Eli Lilly Canada Inc.;2007.
32. GlucaGen® (glucagon) [product monograph]. Bags-vaerd, Denmark: Novo Nordisk; 2002.
33. Kagan A, Hashemi G, Korner-Bitensky N. Diabe-tes and fitness to drive: a systematic review of the evidence with a focus on older drivers. Canadian J Diabetes 2010;34:233-42,D. Clayton et al./Can J Diabetes 37(2013) S69-S71.